<DOC>
	<DOCNO>NCT00383370</DOCNO>
	<brief_summary>To assess safety tolerability repeat intravitreal ( ITV ) administration VEGF Trap .</brief_summary>
	<brief_title>Safety Tolerability Intravitreal VEGF Trap Formulations Subjects With Neovacular AMD</brief_title>
	<detailed_description>A double-masked study approximately 12 subject receive ITV injection VEGF Trap every 4 week total 3 dos . Once subject receive 3 dos allow study , evaluate every 4 week continue dose VEGF Trap additional 9 month .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Subfoveal CNV secondary AMD . Central retinal ( include lesion ) thickness ≥ 250 µm measure OCT. ETDRS bestcorrected visual acuity ( BCVA ) 20/40 20/400 ( 73 20 letter ) No prior treatment follow study eye : Subfoveal thermal laser therapy ; Submacular surgery surgical intervention treatment AMD ; Extrafoveal laser coagulation treatment within 12 week prior Day 1 ( Visit 2 ) ; PDT ITV administration triamcinolone acetonide steroid within 12 week prior Day 1 ( Visit 2 ) ; Pegaptanib sodium within 8 week Day 1 ( Visit 2 ) ; Juxtascleral steroid anecortave acetate within 180 Days ( 6 month ) prior Day 1 ( visit 2 ) ; Prior systemic intravitreal treatment VEGF Trap bevacizumab ; Any investigational agent treatment eye disease within 12 week Day 1 ( Visit 2 ) History vitreous hemorrhage within 4 week prior baseline injection visit . Aphakia pseudophakia absence posterior capsule ( unless occur result yttrium aluminum garnet [ YAG ] capsulotomy ) . Significant subfoveal atrophy scar . Any condition laboratory abnormality , opinion Investigator , would interfere assessment disease status/progression jeopardize subject 's appropriate participation study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>